Keytruda

News

Merck and Lilly expand alliance with Keytruda + Lartruvo tri...

Lilly is to test its new sarcoma treatment Lartruvo in combination with Keytruda, representing yet another combination for Merck Inc's immunotherapy blockbuster.

ESMO2016

Cancer market commentary: Roche’s Tecentriq muscles into NSC...

Roche's PD-L1 drug has generated impressive data in second line lung cancer

ESMO2016

Cancer Market Commentary: Keytruda’s triumph not the last wo...

Despite Keytruda's overwhelming victory, it's not over yet in NSCLC

ESMO2016

Eye on ESMO: Day 1 - Access in spotlight before data deluge

Europe's biggest cancer conference ESMO is underway

News

Merck makes its move: Keytruda filed for first line lung can...

Merck steals a march on rival BMS.

Views & Analysis

Promise for combination approach to cancer

As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.

Merck and Lilly expand alliance with Keytruda + Lartruvo tri...

Cancer market commentary: Roche’s Tecentriq muscles into NSC...

Cancer Market Commentary: Keytruda’s triumph not the last wo...

Eye on ESMO: Day 1 - Access in spotlight before data deluge

Merck makes its move: Keytruda filed for first line lung can...

Promise for combination approach to cancer

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Keytruda

Editor's Picks